1 citations
,
June 2001 in “Annals of Internal Medicine” Troglitazone increases subcutaneous fat in lipodystrophy patients.
1 citations
,
August 2025 GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
2 citations
,
January 2013 in “Iraqi journal of Medical Sciences” March 2026 in “Journal of Pharmaceutical Research” Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.
May 2024 in “Psychiatric News” Weight-loss drugs are not linked to suicidal thoughts.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
April 2026 in “Science Progress” GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
2 citations
,
March 2020 in “Cns & Neurological Disorders-drug Targets” Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.
GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
January 2018 in “Haydarpaşa Numune Hastanesi tıp dergisi” Tamsulosin's sulfonamide group may contribute to floppy iris syndrome.
3 citations
,
July 2025 in “International Immunopharmacology” 4 citations
,
March 2025 in “Journal of Cosmetic Dermatology” Semaglutide may cause hair loss, but more research is needed to confirm this.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
October 2025 in “JEADV Clinical Practice” GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
February 2023 in “Reactions Weekly”
New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
2 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.
July 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Pioglitazone combined with metformin or spironolactone improves PCOS symptoms and insulin resistance.